...
search icon
imcr-img

Immunocore Holdings Ltd, Common Stock

IMCR

NSQ

$29.41

+$1

(3.52%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.33B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
386.39K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.76
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$23.15 L
$62.74 H
$29.41

About Immunocore Holdings Ltd, Common Stock

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIMCRSectorS&P500
1-Week Return9.25%-2.2%-2.34%
1-Month Return-1.34%-7.58%-6.99%
3-Month Return-1.97%-4.92%-12.73%
6-Month Return-11.71%-10.47%-9.81%
1-Year Return-47.31%-2.86%5.41%
3-Year Return-17.29%-2.34%20.18%
5-Year Return-31.92%39.77%92.83%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue30.11M26.52M143.74M249.43M310.20M[{"date":"2020-12-31","value":9.71,"profit":true},{"date":"2021-12-31","value":8.55,"profit":true},{"date":"2022-12-31","value":46.34,"profit":true},{"date":"2023-12-31","value":80.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue74.81M73.23M454.00K1.04M2.73M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.88,"profit":true},{"date":"2022-12-31","value":0.61,"profit":true},{"date":"2023-12-31","value":1.39,"profit":true},{"date":"2024-12-31","value":3.65,"profit":true}]
Gross Profit(44.70M)(46.71M)143.28M248.39M307.47M[{"date":"2020-12-31","value":-14.54,"profit":false},{"date":"2021-12-31","value":-15.19,"profit":false},{"date":"2022-12-31","value":46.6,"profit":true},{"date":"2023-12-31","value":80.79,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(148.42%)(176.12%)99.68%99.58%99.12%[{"date":"2020-12-31","value":-148.89,"profit":false},{"date":"2021-12-31","value":-176.67,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.9,"profit":true},{"date":"2024-12-31","value":99.43,"profit":true}]
Operating Expenses119.40M161.68M182.89M308.04M377.93M[{"date":"2020-12-31","value":31.59,"profit":true},{"date":"2021-12-31","value":42.78,"profit":true},{"date":"2022-12-31","value":48.39,"profit":true},{"date":"2023-12-31","value":81.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(86.19M)(135.16M)(39.61M)(59.65M)(70.46M)[{"date":"2020-12-31","value":-8619300000,"profit":false},{"date":"2021-12-31","value":-13516200000,"profit":false},{"date":"2022-12-31","value":-3960700000,"profit":false},{"date":"2023-12-31","value":-5964900000,"profit":false},{"date":"2024-12-31","value":-7046100000,"profit":false}]
Total Non-Operating Income/Expense(3.57M)27.89M1.25M3.24M24.30M[{"date":"2020-12-31","value":-12.8,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.48,"profit":true},{"date":"2023-12-31","value":11.63,"profit":true},{"date":"2024-12-31","value":87.11,"profit":true}]
Pre-Tax Income(87.36M)(140.93M)(44.15M)(60.89M)(52.94M)[{"date":"2020-12-31","value":-8736000000,"profit":false},{"date":"2021-12-31","value":-14092800000,"profit":false},{"date":"2022-12-31","value":-4414500000,"profit":false},{"date":"2023-12-31","value":-6089000000,"profit":false},{"date":"2024-12-31","value":-5293700000,"profit":false}]
Income Taxes(13.27M)(9.40M)(2.92M)(5.60M)(1.85M)[{"date":"2020-12-31","value":-1326700000,"profit":false},{"date":"2021-12-31","value":-940500000,"profit":false},{"date":"2022-12-31","value":-292100000,"profit":false},{"date":"2023-12-31","value":-560300000,"profit":false},{"date":"2024-12-31","value":-185000000,"profit":false}]
Income After Taxes(74.09M)(131.52M)(41.22M)(55.29M)(51.09M)[{"date":"2020-12-31","value":-7409300000,"profit":false},{"date":"2021-12-31","value":-13152300000,"profit":false},{"date":"2022-12-31","value":-4122400000,"profit":false},{"date":"2023-12-31","value":-5528700000,"profit":false},{"date":"2024-12-31","value":-5108700000,"profit":false}]
Income From Continuous Operations(74.09M)(131.52M)(41.22M)(54.07M)(51.09M)[{"date":"2020-12-31","value":-7409300000,"profit":false},{"date":"2021-12-31","value":-13152300000,"profit":false},{"date":"2022-12-31","value":-4122400000,"profit":false},{"date":"2023-12-31","value":-5407300000,"profit":false},{"date":"2024-12-31","value":-5108700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(74.09M)(131.52M)(41.22M)(55.29M)(51.09M)[{"date":"2020-12-31","value":-7409300000,"profit":false},{"date":"2021-12-31","value":-13152300000,"profit":false},{"date":"2022-12-31","value":-4122400000,"profit":false},{"date":"2023-12-31","value":-5528700000,"profit":false},{"date":"2024-12-31","value":-5108700000,"profit":false}]
EPS (Diluted)(0.83)(93.89)(93.00)(63.59)(0.92)[{"date":"2020-12-31","value":-82.84,"profit":false},{"date":"2021-12-31","value":-9389,"profit":false},{"date":"2022-12-31","value":-9300,"profit":false},{"date":"2023-12-31","value":-6359,"profit":false},{"date":"2024-12-31","value":-92.14,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IMCR
Cash Ratio 3.87
Current Ratio 4.38
Quick Ratio 4.36

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IMCR
ROA (LTM) -4.08%
ROE (LTM) -14.01%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IMCR
Debt Ratio Lower is generally better. Negative is bad. 0.64
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.36

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IMCR
Trailing PE NM
Forward PE NM
P/S (TTM) 4.52
P/B 3.89
Price/FCF NM
EV/R 3.27
EV/Ebitda NM

FAQs

What is Immunocore Holdings Ltd share price today?

Immunocore Holdings Ltd (IMCR) share price today is $29.41

Can Indians buy Immunocore Holdings Ltd shares?

Yes, Indians can buy shares of Immunocore Holdings Ltd (IMCR) on Vested. To buy Immunocore Holdings Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMCR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Immunocore Holdings Ltd be purchased?

Yes, you can purchase fractional shares of Immunocore Holdings Ltd (IMCR) via the Vested app. You can start investing in Immunocore Holdings Ltd (IMCR) with a minimum investment of $1.

How to invest in Immunocore Holdings Ltd shares from India?

You can invest in shares of Immunocore Holdings Ltd (IMCR) via Vested in three simple steps:

  • Click on Sign Up or Invest in IMCR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Immunocore Holdings Ltd shares
What is Immunocore Holdings Ltd 52-week high and low stock price?

The 52-week high price of Immunocore Holdings Ltd (IMCR) is $62.74. The 52-week low price of Immunocore Holdings Ltd (IMCR) is $23.15.

What is Immunocore Holdings Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Immunocore Holdings Ltd (IMCR) is 3.89

What is the Market Cap of Immunocore Holdings Ltd?

The market capitalization of Immunocore Holdings Ltd (IMCR) is $1.33B

What is Immunocore Holdings Ltd’s stock symbol?

The stock symbol (or ticker) of Immunocore Holdings Ltd is IMCR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top